GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. NAFLD can further progress to irreversible liver failure such as non-alcoholic steatohepatitis (NASH) fibrosis and cirrhosis. However, specific regulator of NASHfibrosis has yet to be established. Here, we found that glutathione peroxidase 7 (GPx7) was markedly expressed in NASH fibrosis. Although GPx7 is an antioxidant enzyme protecting other organs, whether GPx7 plays a role in NASH fibrosis has yet to be studied. We found that knockdown of GPx7 in transforming growth factor- (TGF-) and free fatty acids (FFA)- treated LX-2 cells elevated the expression of pro-fibrotic and pro-inflammatory genes and collagen synthesis. Consistently, GPx7 overexpression in LX-2 cells led to the suppression of ROS production and reduced the expression of pro-fibrotic and pro-inflammatory genes. Further, NASH fibrosis induced by choline-deficient amino acid defined, high fat diet (CDAHFD) feeding was significantly accelerated by knockdown of GPx7, as evidenced by up-regulated liver fibrosis and inflammation compared with CDAHFD control mice. Collectively, these results suggest that GPx7 might be a novel therapeutic target to prevent the progression and development of NAFLD.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. NAFLD can further progress to irreversible liver failure such as non-alcoholic steatohepatitis (NASH) fibrosis and cirrhosis. However, specific regulator of NASHfibrosis has yet to be established. Here, we found that glutathione peroxidase 7 (GPx7) was markedly expressed in NASH fibrosis. Although GPx7 is an antioxidant enzyme protecting other organs, whether GPx7 plays a role in NASH fibrosis has yet to be studied. We found that knockdown of GPx7 in transforming growth factor- (TGF-) and free fatty acids (FFA)- treated LX-2 cells elevated the expression of pro-fibrotic and pro-inflammatory genes and collagen synthesis. Consistently, GPx7 overexpression in LX-2 cells led to the suppression of ROS production and reduced the expression of pro-fibrotic and pro-inflammatory genes. Further, NASH fibrosis induced by choline-deficient amino acid defined, high fat diet (CDAHFD) feeding was significantly accelerated by knockdown of GPx7, as evidenced by up-regulated liver fibrosis and inflammation compared with CDAHFD control mice. Collectively, these results suggest that GPx7 might be a novel therapeutic target to prevent the progression and development of NAFLD.
참고문헌 (32)
- Buzzetti E, "The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)", Metabolism, 65, pp.1038~1048 (2016)
- Hardy T, "Nonalcoholic Fatty Liver Disease : Pathogenesis and Disease Spectrum", Annu Rev Pathol, 11, pp.451~496 (2016)
- Cohen JC, "Human fatty liver disease : old questions and new insights", Science, 332, pp.1519~1523 (2011)
- Szczepaniak LS, "Magnetic resonance spectroscopy to measure hepatic triglyceride content : prevalence of hepatic steatosis in the general population", Am J Physiol Endocrinol Metab, 288, pp.E462~468 (2005)
- Promrat K, "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis", Hepatology, 51, pp.121~129 (2010)
- Huang MA, "One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis : a pilot study", Am J Gastroenterol, 100, pp.1072~1081 (2005)
- Tacke F, "Mechanisms of liver fibrosis resolution", J Hepatol, 63, pp.1038~1039 (2015)
- Bataller R, "Liver fibrosis", J Clin Invest, 115, pp.209~218 (2005)
- 정선혜, "Insulin receptor substrate 2: a bridge between Hippo and AKT pathways", BMB Reports, 51(5), pp.209~210 (2018), 생화학분자생물학회
- Stal P, "Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance", World J Gastroenterol, 21, pp.11077~11087 (2015)
- Yang KL, "Prevention of TGF-beta-induced early liver fibrosis by a maleic acid derivative anti-oxidant through suppression of ROS, inflammation and hepatic stellate cells activation", PLoS One, 12, pp.e0174008~ (2017)
- Iwaisako K, "What’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis", J Gastroenterol Hepatol, 27(Suppl 2), pp.65~68 (2012)
- Gandhi CR, "Oxidative Stress and Hepatic Stellate Cells : A PARADOXICAL RELATIONSHIP", Trends Cell Mol Biol, 7, pp.1~10 (2012)
- Torok NJ, "Dysregulation of redox pathways in liver fibrosis", Am J Physiol Gastrointest Liver Physiol, 311, pp.G667~G674 (2016)
- Sanchez-Valle V, "Role of oxidative stress and molecular changes in liver fibrosis : a review", Curr Med Chem, 19, pp.4850~4860 (2012)
- Muthukumar K, "Cadmiuminduced oxidative stress in Saccharomyces cerevisiae", Indian J Biochem Biophys, 47, pp.383~387 (2010)
- Chen YI, "NPGPx(GPx7) : a novel oxidative stress sensor", transmitter with multiple roles in redox homeostasis, 2016, pp.8, 1626~1640
- Peng D, "Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells", Gut, 61, pp.1250~1260 (2012)
- Peng D, "Glutathione peroxidase 7 has potential tumour suppressor functions that are silenced by location-specific methylation in oesophageal adenocarcinoma", Gut, 63, pp.540~551 (2014)
- Peng DF, "Loss of glutathione peroxidase 7 promotes TNF-alpha-induced NF-kappaB activation in Barrett's carcinogenesis", Carcinogenesis, 35, pp.1620~1628 (2014)
- Mehmeti I, "ER-resident antioxidative GPx7 and GPx8 enzyme isoforms protect insulin-secreting INS-1E beta-cells against lipotoxicity by improving the ER antioxidative capacity", Free Radic Biol Med, 112, pp.121~130 (2017)
- Fujita T, "Roles of hepatic stellate cells in liver inflammation : a new perspective", Inflamm Regen, 36, pp.1~ (2016)
- Benedict M, "Non-alcoholic fatty liver disease : An expanded review", World J Hepatol, 9, pp.715~732 (2017)
- Del Campo JA, "Role of inflammatory response in liver diseases : Therapeutic strategies", World J Hepatol, 10, pp.1~7 (2018)
- Lo RC, "Histopathological evaluation of liver fibrosis and cirrhosis regression", Clin Mol Hepatol, 23, pp.302~307 (2017)
- Higashi T, "Hepatic stellate cells as key target in liver fibrosis", Adv Drug Deliv Rev, 121, pp.27~42 (2017)
- Safadi R, "Hepatic fibrosis--role of hepatic stellate cell activation", MedGenMed, 4, pp.27~27 (2002)
- Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
- Zhou Z, "Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis", Cell Mol Gastroenterol Hepatol, 5, pp.399~413 (2018)
- Jing XY, "Roles of the lipid metabolism in hepatic stellate cells activation big up tri, open", Chin Med Sci J, 28, pp.233~236 (2013)
- Novo E, "Cellular and molecular mechanisms in liver fibrogenesis", Arch Biochem Biophys, 548, pp.20~37 (2014)
- 이다현, "Inactivation of Sirtuin2 protects mice from acetaminophen-induced liver injury: possible involvement of ER stress and S6K1 activation", BMB Reports, 52(3), pp.190~195 (2019), 생화학분자생물학회[DOI]